Statements

CSRxP APPLAUDS REINTRODUCTION OF REMEDY ACT IN U.S. SENATE 

Jul 31, 2024

Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive Read More

CSRXP: BIG PHARMA IS AT IT AGAIN, HIKES PRICES ON NEARLY 200 PRESCRIPTION DRUGS AS PART OF MID-YEAR INCREASES

Jul 15, 2024

Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate Read More

CSRXP APPLAUDS U.S. SENATE PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTION TO CRACK DOWN ON BIG PHARMA’S PATENT THICKETS

Jul 11, 2024

Legislation Would Hold Big Pharma Accountable for Anti-Competitive Tactics Read More

NEW GOODRX REPORT UNDERSCORES NEED FOR CONGRESS TO HOLD BIG PHARMA ACCOUNTABLE

Jul 2, 2024

Latest Data Finds List Prices of Prescription Drug Prices Have Increased Read More

CSRXP COMMENDS PRESIDENT BIDEN FOR HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE AND EGREGIOUS PRICING ON BRAND NAME INHALERS

Apr 3, 2024

President Says ‘Drug Companies Are Charging Exorbitant Prices’ in Press Read More

CSRXP APPLAUDS FTC CRACKDOWN ON BIG PHARMA’S FLAGRANT ABUSE OF THE PATENT SYSTEM

Nov 7, 2023

Commission Targets More Than 100 Patents on Brand Name Products Listed in the Read More

CSRXP COMMENDS HELP COMMITTEE FOR ADVANCING BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE

May 11, 2023

Senate Panel Passes Bills to Increase Competition and Increase List Price Read More